Medical oncology and tumor pharmacotherapy最新文献_第3页

Reflections on human tumor immunology. 关于人类肿瘤免疫学的思考。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987773

E Klein

引用次数: 0

T-lymphocyte sub-populations in orbito-ocular granulocytic sarcoma (OOGS) and acute myelocytic leukemia (AML): a preliminary study. 眼眶-眼粒细胞肉瘤(OOGS)和急性髓细胞性白血病(AML)的t淋巴细胞亚群:初步研究。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987777

A O Cavdar, E Babacan, S Gözdasoglu, G Yavuz, E Unal, A Pamir

引用次数: 11

The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC). 非偶联单克隆抗体(MAb) 17-1A联合GM-CSF治疗结直肠癌(CRC)的临床应用

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987770

P Ragnhammar, I Magnusson, G Masucci, H Mellstedt

{"title":"The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).","authors":"P Ragnhammar, I Magnusson, G Masucci, H Mellstedt","doi":"10.1007/BF02987770","DOIUrl":"https://doi.org/10.1007/BF02987770","url":null,"abstract":"Unconjugated monoclonal antibodies (MAb) and granulocyte macrophage-colony stimulating factor (GM-CSF) may induce tumor regression in patients. Antibody-dependent cellular cytotoxicity (ADCC) is considered to be one of the effector functions of MAb. Human peripheral blood mononuclear cells (PBMC) preincubated with GM-CSF and used as effector cells in an 18h ADCC assay with SW948 (human colorectal carcinoma cell line) as target cells and MAb 17-1A induced significant increase in the lytic capacity of the effector cells. Based on these findings the therapeutic effect of the combination of mouse MAb 17-1A (IgG2a) against colorectal carcinoma (CRC) cells and GM-CSF was evaluated in 20 patients with metastatic CRC. The patients received GM-CSF (250 micrograms/m2/day s.c.) for 10 days and a single i.v. infusion of MAb 17-1A (400 mg) at day 3 of the cycle. The cycles were repeated with an interval of one month. Four cycles were given. ADCC as well as Fc-receptor bearing mononuclear cells increased significantly during therapy. Two patients achieved CR (10%). One patient had an MR (5%) and a further three patients were considered to have SD > 3 months (15%). The two CR patients are still in CR, 35+ and 30+ months respectively after initiation of therapy. Patients with an ADCC activity at start of therapy above the median value of the total patient material survived significantly longer than those patients with an ADCC reactivity below this value (p = 0.002).","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 1-2","pages":"61-70"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987770","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19248111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: I. Application of the HEV-binding assay to a clinical series. b细胞慢性淋巴细胞白血病中粘附分子的表达和归巢:I. hev结合试验在临床系列中的应用。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987779

G Csanaky, V Kalász, G Kelényi, H Losonczy, Z Balikó, A Tóth

{"title":"Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: I. Application of the HEV-binding assay to a clinical series.","authors":"G Csanaky, V Kalász, G Kelényi, H Losonczy, Z Balikó, A Tóth","doi":"10.1007/BF02987779","DOIUrl":"https://doi.org/10.1007/BF02987779","url":null,"abstract":"High endothelial venule (HEV)-binding of peripheral blood mononuclear cells (PBMCs) from 43 patients with B-cell chronic lymphocytic leukaemia (B-CLL) was investigated with a HEV-binding in vitro assay. Immunophenotyping of HEV-adherent PBMCs proved that most of them belonged to the B-cell proliferation. B-CLL cells stringently expressed CD44 molecules (Hermes-1, -3 and H90). The patients were subgrouped according to Binet's classification, as well as according to the organ manifestations, i.e. patients with B-cell monoclonal lymphocytosis of undetermined significance (B-MLUS) and patients with lymphocytosis (LY), lymph node enlargement (LN) and splenomegaly (SM). The HEV-binding activity of the cells was the highest in Binet stage A patients and in patients with B-MLUS (p < 0.05 in B-MLUS versus B-CLL LY, LN, SM). Based on these findings it is suggested that B-CLL patients show not only a clinical and immunophenotypical heterogeneity, but a diverse function of adhesion molecules.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 3","pages":"125-30"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987779","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19252706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Cerebral arterial disturbances in a transient encephalopathy induced by methotrexate. 甲氨蝶呤诱发的一过性脑病的脑动脉紊乱。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02989667

J Y Follezou, L Chauveinc, J M Guerin

引用次数: 2

Special issue: Biological response modifiers. Proceedings of an international symposium. 16-20 November 1992. 特刊:生物反应调节剂。国际研讨会论文集。1992年11月16日至20日。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01

引用次数: 0

Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. 抗白细胞介素-6 (IL-6)小鼠单克隆抗体在急性单细胞白血病患者中的作用。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02989668

R Bataille, X G Zhang, J Wijdenes, J F Schved, B Klein

引用次数: 8

Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts. AML原细胞刺激诱导细胞毒性淋巴细胞亚群抗白血病。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987763

E Lotzová, C A Savary

引用次数: 3

Monoclonal antibodies and superantigens: a novel therapeutic approach. 单克隆抗体和超级抗原:一种新的治疗方法。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987767

T Kalland, M Dohlsten, P Lind, A Sundstedt, L Abrahmsén, G Hedlund, P Björk, P A Lando, M Björklund

引用次数: 7

Clinical evaluation of the CORDIS vascular access port systems: a multicenter study. CORDIS血管通路系统的临床评价:一项多中心研究。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987780

A Hoekstra, V Bassot, S Bertoglio, J Y Bobin, P Delassus, R Egeli, D Khayat, J Y Ranchere, J Santini, P Segol

{"title":"Clinical evaluation of the CORDIS vascular access port systems: a multicenter study.","authors":"A Hoekstra, V Bassot, S Bertoglio, J Y Bobin, P Delassus, R Egeli, D Khayat, J Y Ranchere, J Santini, P Segol","doi":"10.1007/BF02987780","DOIUrl":"https://doi.org/10.1007/BF02987780","url":null,"abstract":"Two non-metallic vascular access port systems, the Multipurpose Access Port (MPAP) and Miniport, developed by CORDIS S.A., France, have been evaluated clinically in 78 cancer patients. During the investigational period covering a total experience of 369 treatment cycles and 1,370 infusion days, no cases of infection or septicemia were observed. Serious complications such as drug extravasation and catheter occlusion occurred, although the incidence was relatively low (+/- 1%) when compared with the number of treatment courses (cycles), but in relation to the number of patients included in this study, the procedure-related complication rate was 17.5% for the MPAP and 15.8% for the Miniport. Procedure-related complications can be avoided by proper handling and use of suitable drug combinations to minimize crystallization reactions within the port-catheter systems. The final complication rate (total minus procedure-related) in terms of termination of treatment, i.e. explantation of the port-catheter system was 12.1% for the MPAP and 12.5% for the MINIPORT, which generally confirms the results of other groups. More than 87% of both port-catheter systems were still functional at the end of evaluation.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 3","pages":"131-8"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987780","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19252707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5